First, they demonstrate that combined application of adavosertib, a drug inhibiting WEE1, and prexasertib, a drug targeting CHK1, is highly cytotoxic in four TP53 and CDKN2A-mutated HNSCC cell lines. Here, CDKN2A is linked to head and neck squamous cell carcinoma.